Abstract 1572: Broad glutamine pathway inhibition by DRP-104 results in anti-tumor activity in hypermetabolic lung tumors resistant to PD-1 or osimertinib therapy

作者
Morgan R. Brady,Milica Momcilovic,Chiara Montemurro,Yumi Yokoyama,Heather R. Christofk,Katerina A. Politi,Margaret Han Dugan,Aaron Elliott Lisberg,Robert Wild,David B. Shackelford
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:81 (13_Supplement): 1572-1572 被引量:2
标识
DOI:10.1158/1538-7445.am2021-1572
摘要

Abstract Recent breakthroughs with checkpoint inhibitors (CPI) or the third generation tyrosine kinase inhibitor (TKI) osimertinib (OSI) for patients with specific mutations to the epidermal growth factor receptor (EGFR) gene are now able to induce durable responses in non-small cell lung cancer (NSCLC) patients1,2. However, the majority of patients who receive CPI or OSI will be either non-responsive to treatment or develop therapy resistance. We sought to identify alternative treatment strategies to overcome therapy resistance by targeting metabolism in aggressive tumors. The fast rate of growth in therapy resistant hyper-metabolic tumors (HMTs) makes them dependent on nutrients to sustain anabolic growth. To demonstrate this dependency, we coupled PET imaging using 18F-FDG and 11C-Glutamine (11C-GLN) with in vivo metabolomics and identified a conserved metabolic signature in which lung squamous cell carcinomas (LUSC) and EGFR mutant lung adenocarcinomas (LUAD) were marked by dependence upon both glucose and glutamine3,4. Importantly, this metabolic signature is predictive of either response or resistance to targeted therapies that inhibit glucose and glutamine metabolism that may be exploited in a clinical setting.We previously reported that combined targeting of glucose and glutamine metabolism with mTOR kinase inhibitor TAK228 or TKI in combination with the selective glutaminase (GLS) inhibitor CB-839 was required to significantly suppress glucose and glutamine metabolism in both LUSC and EGFR mutant LUADs resulting in metabolic crisis and tumor cell death3,5. Here, we tested the novel broad acting glutamine antagonist, DRP-104, as a single agent or in combination with anti-PD-1 in CPI-resistant LUSC and in EGFR mutant LUAD tumor models. DRP-104 significantly inhibited tumor progression across genetically engineered mouse models (GEMMs) with biallelic deletion of lkb1, pten and p53 (Lkb1-/-;Pten-/-;P53-/-) and patient derived xenograft (PDX) models of LUSC. Importantly, LUSC showed significant single agent response to DRP-104 and the combination of DRP-104 and anti-PD-1 treatment demonstrated therapeutic synergy, suggesting that broad inhibition of glutamine metabolism by DRP-104 induced metabolic remodeling of the tumor immune microenvironment and permissiveness to CPI blockade6. Likewise, we showed that DRP-104 induced a significant response in an OSI-resistant PDX model of EGFR mutant LUAD. Overall, DRP-104 showed great potential to treat hypermetabolic therapy-resistant LUSC and EGFR mutant LUAD as a single-agent therapy and in combination with immune CPI. Further clinical development of DRP-104 in this patient population is warranted and clinical trials are currently ongoing. Citation Format: Morgan Brady, Milica Momcilovic, Chiara Montemurro, Yumi Yokoyama, Heather Christofk, Katerina Politi, Margaret Dugan, Aaron Lisberg, Robert Wild, David B. Shackelford. Broad glutamine pathway inhibition by DRP-104 results in anti-tumor activity in hypermetabolic lung tumors resistant to PD-1 or osimertinib therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1572.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
何苗发布了新的文献求助10
刚刚
大个的应助被cindy采纳,获得10
刚刚
罐装完成签到,获得积分20
2秒前
2秒前
风一样的我完成签到 ,获得积分0
3秒前
D_完成签到,获得积分10
4秒前
小二郎的应助被烂漫的灰狼采纳,获得10
4秒前
5秒前
5秒前
XX发布了新的文献求助10
7秒前
平凡的豆包完成签到,获得积分20
7秒前
Jin完成签到 ,获得积分10
7秒前
NexusExplorer的应助被李子采纳,获得10
8秒前
9秒前
10秒前
ing完成签到 ,获得积分10
10秒前
竹马子完成签到,获得积分10
10秒前
悠旷完成签到 ,获得积分10
10秒前
10秒前
cindy发布了新的文献求助20
11秒前
念安发布了新的文献求助10
11秒前
12秒前
星辰大海的应助被苏文涛采纳,获得10
12秒前
12秒前
Patti完成签到,获得积分10
12秒前
Yogita完成签到,获得积分10
12秒前
俭朴的鸽子完成签到 ,获得积分10
12秒前
百里伟祺完成签到 ,获得积分10
14秒前
sun完成签到,获得积分10
15秒前
重回地球发布了新的文献求助10
15秒前
故城完成签到 ,获得积分10
15秒前
luyue9406的应助被cmn采纳,获得10
16秒前
LLL发布了新的文献求助10
16秒前
luyue9406的应助被霸气的亿先采纳,获得10
17秒前
大模型的应助被HudsonWei采纳,获得10
17秒前
Sunmq完成签到,获得积分10
17秒前
17秒前
18秒前
什么也难不倒我完成签到 ,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168144
求助须知:如何正确求助?哪些是违规求助? 9561199
关于积分的说明 21759542
捐赠科研通 7759434
什么是DOI,文献DOI怎么找? 3429948
关于科研通互助平台的介绍 2553742
邀请新用户注册赠送积分活动 2474463